Fujin - Detecting Lung Cancer in early stage with non-invasive method

50% of lung cancer patients are diagnosed in late stages, having 8 times less chances of having successful treatment and presenting a financial burden of US$ 36 billion in North America.  Late symptoms, distances and lack of capacity of covering CT scan yearly expenses are the main causes.

Fujin provides a non-invasive diagnostic system that doesn't depend on medical facilities, using the patient's breath.

Sick lung cells breathe in a different way of healthy ones, generating special kinds of cases that we call Volatile Organic Components (VOCs).  When the VOCs correspond to a certain kind of cell, we call them biomarkers, and we can use them for diagnostics, like the ones in blood.

We are going to clinical trials right now, to determine the accuracy of our method.

He were accelerated by Centech / ÉTS and have support from the province of Québec and the city of Montréal

Fujin technology has been patented, providing protection for the method, that can be also applied to other diseases